Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00060138
Other study ID # CWRU-080235
Secondary ID CDR0000299530CBI
Status Completed
Phase Phase 1/Phase 2
First received May 6, 2003
Last updated May 13, 2013
Start date November 2002

Study information

Verified date May 2013
Source Chugai Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than zoledronate in treating women who have breast cancer and bone metastases.

PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with that of zoledronate in treating women who have breast cancer and bone metastases.


Description:

OBJECTIVES:

- Compare the safety and tolerability of monoclonal antibody CAL vs zoledronate in women with breast cancer and bone metastases.

- Compare, preliminarily, the potential effects of these drugs on skeletal events/manifestations related to bone metastases, including hypercalcemia, bone pain, bone metastatic lesions, complications (e.g., pathologic fracture and spinal cord compression), and interventions (e.g., surgery and radiotherapy) in these patients.

- Compare changes in ECOG performance status in patients treated with these drugs.

- Determine the pharmacokinetics of monoclonal antibody CAL in these patients.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to average prestudy pain score on question 3 of a daily electronic telephone pain diary (less than 3 vs 3 or more) and prior bisphosphonate therapy (yes vs no). Patients are randomized to 1 of 4 treatment arms.

- Arm I: Patients receive monoclonal antibody CAL IV over 30-60 minutes on day 1.

- Arm II: Patients receive a lower dose of monoclonal antibody CAL as in arm I.

- Arm III: Patients receive a lower dose (lower than arm II) of monoclonal antibody CAL as in arm I.

- Arm IV: Patients receive zoledronate IV over 30-60 minutes on day 1. Treatment in all arms repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients keep a pain diary throughout study participation.

Patients are followed at 24 weeks.

PROJECTED ACCRUAL: A total of 72 patients (18 per treatment arm) will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date September 2004
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed breast cancer

- Radiographical evidence of at least 1 bone metastasis

- No prior radiotherapy or surgery to bone metastasis

- No radiotherapy or surgery anticipated for bone metastasis within the next 24 weeks

- Bone pain severity score of at least 1 on 5 of 7 days as determined by question 3 of the Brief Pain Inventory (BPI)

- No bone metastases to a weight-bearing bone at imminent risk for pathologic fracture or surgical intervention

- No vertebral metastases that place the patient at imminent risk of spinal cord compression

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS:

Age

- 18 and over

Sex

- Female

Menopausal status

- Pre- or post-menopausal

Performance status

- ECOG 0-2

Life expectancy

- At least 6 months

Hematopoietic

- WBC at least 2,000/mm^3

- Lymphocyte count at least 500/mm^3

- Granulocyte count at least 1,000/mm^3

- Platelet count at least 50,000/mm^3

Hepatic

- ALT or AST no greater than 2.5 times upper limit of normal (ULN)

- Bilirubin no greater than 1.5 times ULN

Renal

- Calcium no greater than 10.1 mg/dL

- No oliguria, defined as less than 30 mL urine per 2-hour collection

- No acute renal failure

- Creatinine no greater than 2.5 mg/dL

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception

- No sepsis

- No known or anticipated contraindication to study drugs

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- More than 3 weeks since initiation of a new chemotherapy regimen

Endocrine therapy

- More than 3 weeks since initiation of a new hormonal therapy regimen

Radiotherapy

- See Disease Characteristics

- More than 3 weeks since prior radiotherapy

Surgery

- See Disease Characteristics

Other

- More than 60 days since prior bisphosphonates

- More than 30 days since prior investigational drugs

- No change in analgesic drug regimen during the screening period

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care


Intervention

Biological:
monoclonal antibody CAL

Drug:
zoledronic acid


Locations

Country Name City State
United States Ireland Cancer Center Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
Chugai Pharmaceutical National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2